Candriam SCA’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.2M | Sell |
34,518
-29,497
| -46% | -$16.5M | 0.08% | 214 |
|
|
2026
Q1 | $36M | Buy |
64,015
+13,456
| +27% | +$8.63M | 0.19% | 125 |
|
|
2025
Q4 | $34.2M | Buy |
50,559
+27,584
| +120% | +$18.8M | 0.17% | 132 |
|
|
2025
Q3 | $14.7M | Sell |
22,975
-56,053
| -71% | -$34M | 0.08% | 216 |
|
|
2025
Q2 | $42.4M | Sell |
79,028
-3,163
| -4% | -$1.51M | 0.24% | 92 |
|
|
2025
Q1 | $34.5M | Buy |
82,191
+53,647
| +188% | +$23.3M | 0.22% | 102 |
|
|
2024
Q4 | $11.8M | Buy |
28,544
+5,610
| +24% | +$2.46M | 0.07% | 242 |
|
|
2024
Q3 | $11.6M | Buy |
22,934
+4,850
| +27% | +$2.36M | 0.07% | 254 |
|
|
2024
Q2 | $8.81M | Sell |
18,084
-7,454
| -29% | -$3.74M | 0.05% | 274 |
|
|
2024
Q1 | $13.8M | Sell |
25,538
-9,098
| -26% | -$4.97M | 0.09% | 216 |
|
|
2023
Q4 | $19.2M | Sell |
34,636
-599
| -2% | -$281K | 0.13% | 162 |
|
|
2023
Q3 | $15.4M | Buy |
35,235
+29,154
| +479% | +$14.5M | 0.11% | 177 |
|
|
2023
Q2 | $3.05M | Sell |
6,081
-8,409
| -58% | -$4.03M | 0.02% | 423 |
|
|
2023
Q1 | $6.67M | Sell |
14,490
-2,251
| -13% | -$1.08M | 0.05% | 314 |
|
|
2022
Q4 | $6.83M | Buy |
16,741
+984
| +6% | +$382K | 0.05% | 331 |
|
|
2022
Q3 | $5.13M | Buy |
15,757
+9,622
| +157% | +$3.53M | 0.04% | 375 |
|
|
2022
Q2 | $2.15M | Sell |
6,135
-50,556
| -89% | -$20.6M | 0.02% | 489 |
|
|
2022
Q1 | $31M | Buy |
56,691
+3,046
| +6% | +$1.6M | 0.21% | 112 |
|
|
2021
Q4 | $35.3M | Buy |
53,645
+9,819
| +22% | +$6.16M | 0.23% | 116 |
|
|
2021
Q3 | $27.3M | Sell |
43,826
-6,100
| -12% | -$4.1M | 0.19% | 130 |
|
|
2021
Q2 | $31.5M | Buy |
49,926
+43,592
| +688% | +$24.1M | 0.22% | 107 |
|
|
2021
Q1 | $3.04M | Hold |
6,334
| – | – | 0.03% | 453 |
|
|
2020
Q4 | $3.17M | Sell |
6,334
-13,622
| -68% | -$6.1M | 0.03% | 464 |
|
|
2020
Q3 | $7.84M | Sell |
19,956
-5,258
| -21% | -$1.94M | 0.07% | 271 |
|
|
2020
Q2 | $8.32M | Buy |
25,214
+18,061
| +252% | +$5.23M | 0.09% | 244 |
|
|
2020
Q1 | $1.83M | Hold |
7,153
| – | – | 0.02% | 544 |
|
|
2019
Q4 | $1.87M | Buy |
7,153
+1,358
| +23% | +$358K | 0.02% | 560 |
|
|
2019
Q3 | $1.58M | Sell |
5,795
-379
| -6% | -$105K | 0.02% | 540 |
|
|
2019
Q2 | $1.69M | Hold |
6,174
| – | – | 0.02% | 554 |
|
|
2019
Q1 | $1.38M | Buy |
6,174
+250
| +4% | +$51.6K | 0.02% | 566 |
|
|
2018
Q4 | $1.1M | Hold |
5,924
| – | – | 0.02% | 576 |
|
|
2018
Q3 | $1.48M | Buy |
5,924
+289
| +5% | +$70.2K | 0.02% | 557 |
|
|
2018
Q2 | $1.23M | Buy |
+5,635
| New | +$1.16M | 0.02% | 572 |
|
|
2018
Q1 | – | Sell |
-2,010
| Closed | -$314K | – | 771 |
|
|
2017
Q4 | $314K | Sell |
2,010
-2,680
| -57% | -$422K | 0.01% | 715 |
|
|
2017
Q3 | $729K | Sell |
4,690
-19,521
| -81% | -$3.09M | 0.01% | 614 |
|
|
2017
Q2 | $3.91M | Buy |
+24,211
| New | +$3.93M | 0.07% | 316 |
|
Other funds holding IDXX
Candriam SCA's IDXX Position: Q2 2026 in Review
Candriam SCA reduced its Idexx Laboratories (IDXX) stake by 46% in Q2 2026, selling an estimated $16.5M and leaving 34,518 shares worth $18.2M. The position accounts for 0.08% of the portfolio, ranked #214.
Candriam SCA first reported a position in IDXX in Q2 2017 and has held it in 36 quarters since. The position peaked at $42.4M in Q2 2025. 1,296 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Candriam SCA held 34,518 shares of Idexx Laboratories worth $18.2M as of Q2 2026.
- Candriam SCA sold 29,497 Idexx Laboratories shares in Q2 2026, an estimated $16.5M.
- Idexx Laboratories made up 0.08% of Candriam SCA's portfolio in Q2 2026, its #214 holding.
- Candriam SCA first reported a position in Idexx Laboratories in Q2 2017 and has held it in 36 quarters since.
- Candriam SCA's Idexx Laboratories position peaked at $42.4M in Q2 2025.
- 1,296 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.